Form 4: Opaleye Management Inc. Reduces Stake in Protara Therapeutics

Opaleye Management Inc. reports selling shares of Protara Therapeutics (TARA) on June 27 and 28, 2024, resulting in a decreased beneficial ownership.

Summary

• Opaleye Management Inc., a 10% owner of Protara Therapeutics, Inc. (TARA), filed a Form 4 detailing changes in beneficial ownership.
• On June 27, 2024, Opaleye Management Inc. sold 34,103 shares of common stock at a weighted average price of $2.2581, reducing its holdings through Opaleye, L.P.
• Additionally, on June 27, 2024, 12,471 shares were sold from a managed account at $2.2581.
• On June 28, 2024, Opaleye Management Inc. sold 12,994 shares at a weighted average price of $2.0748 through Opaleye, L.P.
• Furthermore, on June 28, 2024, 5,000 shares were sold from a managed account at $2.0748.
• Following these transactions, Opaleye, L.P. beneficially owns 2,219,262 shares, and the managed account owns 85,000 shares.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the reduction in Opaleye's stake, which could indicate a lack of confidence or a shift in investment strategy. However, without further context, it's difficult to assess the full impact.

Negatives

• Opaleye Management Inc. reduced its stake in Protara Therapeutics, which could be interpreted negatively by the market.

Risks

• Continued selling pressure from Opaleye Management Inc. could further depress the stock price.
• The reasons for Opaleye's selling activity are not disclosed, creating uncertainty.

Industry Context

Form 4 filings are standard disclosures for significant shareholders and provide transparency into insider trading activity. The market often interprets these filings as signals, although the reasons for the transactions are not always clear.

Stakeholder Impact

• Shareholders may react to the news of Opaleye Management Inc.'s reduced stake.
• The stock price could be affected by the selling activity.

Key Dates